Page 1 of 1
3 The article, Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre tr
Posted: Wed May 11, 2022 7:53 am
by answerhappygod
- 3 The Article Remdesivir In Adults With Severe Covid 19 A Randomised Double Blind Placebo Controlled Multicentre Tr 1 (38.85 KiB) Viewed 30 times
3 The article, Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial, Lancet, 395(10236), pp. 1569-1578, May 16, 2020, by Y. Wang and et. al, reports the following study for the treatment of severe cases of SARS-CoV-2 virus infection with an experimental medicine, Remdesivir, originally made for Ebola. "237 patients were enrolled and randomly assigned to a treatment group or a control group (158 to Remdesivir and 79 to placebo)." The results of the study includes the 28 day mortality rates of 13.9% for the Remdesivir group and 12.8% for the control group, and the 28 day clinical improvement rates of 65.2% for the Remdesivir group and 57.7% for the control group. Be sure to justify all steps both analytically and graphically. (a) Find the 96% confidence interval of the difference of the 28 day clinical improvement rate between the two groups. (b) Does the study suggest that Remdesivir helped improving the 28 day clinical improve ment rate? Set up your hypotheses and test them with the significance level of a = 0.05.